Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • General meetings
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
3 February 2021 Nasdaq Stockholm Welcomes Scandion Oncology to the Nasdaq First North Growth Market Download Presentation Webcast Workbook
13 January 2020 Peter Høngaard interviewed by Bio Stock Download Presentation Webcast Workbook
11 March 2019 Presentation video in relation to year-end report Download Presentation Webcast Workbook
22 February 2019 Year End Report for 2018 Download Presentation Webcast Workbook
30 December 2018 Senior executives increase their holdings in Scandion Oncology Download Presentation Webcast Workbook
6 August 2018 Scandion Oncology A/S signs agreement with Sedermera Fondkommission AB regarding an Initial Public Offering at Spotlight Stock Market. Download Presentation Webcast Workbook
17 May 2017 New Saniona spinout focused on cancer therapy Download Presentation Webcast Workbook
15 May 2017 Saniona satser på spinout-virksomheder Download Presentation Webcast Workbook
14 May 2017 Nyt Saniona-spinout har fokus på kræft Download Presentation Webcast Workbook
  1. Frontpage

About us

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Image library items
  • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.